SCIPIO patients show sustained improvement
U of L, Harvard researchers also report no safety issues in phase I trial.
University of Louisville Dr. Roberto Bolli, along with Dr. Piero Anversa of Harvard, presented more positive data from their SCIPIO research at the American Heart Association Scientific Sessions 2012 in Los Angeles.
Marked sustained improvement in all patients with zero adverse effects.
For a phase I clinical trial, these results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women’s Hospital reported just such almost-never-attained data.
In a Late-Breaking Clinical Trial session on Nov. 6 at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women’s Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.
RELATED ARTICLES
-
Cardiac stem cell research featured by WebMD (Aug. 23, 2012)
-
Bolli, SCIPIO featured by WHAS-11 (Nov. 10, 2011)
-
U of L, Bolli score again (Sept. 9, 2011)
-
Bolli, U of L to lead multi-center cardioprotective study (Feb. 4, 2011)
-
Cardiac stem cells safe, effective in heart failure treatment (Nov. 15, 2010)
MORE COVERAGE
